modelCeftarolineFosamil
Extends from Pharmacolibrary.Drugs.ATC.J.J01DI02.
Information
| name: | CeftarolineFosamil | |
| ATC code: | J01DI02 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 600 | mg |
| volume of distribution: | 20.3 | L |
| clearance: | 9.7 | L/h |
| other parameters in model implementation | ||
Ceftaroline fosamil is a broad-spectrum, fifth-generation cephalosporin antibiotic approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults and children. It is active against a range of Gram-positive and Gram-negative organisms, including methicillin-resistant Staphylococcus aureus (MRSA). The drug is administered as a prodrug (fosamil form), which is rapidly converted to the active ceftaroline in vivo.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult subjects following intravenous administration.
References
Edlinger-Stanger, M, et al., & Hutschala, D (2021). Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an . Antimicrobial agents and chemotherapy 65(10) e0067921–None. DOI:10.1128/AAC.00679-21 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34280013
Van Wart, SA, et al., & Ambrose, PG (2013). Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Journal of clinical pharmacology 53(11) 1155–1167. DOI:10.1002/jcph.153 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23907740
Bradley, JS, et al., & Leister-Tebbe, HK (2020). Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis. The Pediatric infectious disease journal 39(5) 411–418. DOI:10.1097/INF.0000000000002607 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32091493
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)